Overview

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
Phase II randomized open-label, two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC)
Phase:
Phase 2
Details
Lead Sponsor:
Celgene Corporation
Treatments:
Hormones
Pomalidomide
Thalidomide